EMA Authorised: Xadago (safinamide methanesulfonate) — Zambon SpA

View source ↗

Summary

The EMA authorised Xadago (safinamide methanesulfonate) for Parkinson disease; Zambon SpA is the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Xadago (safinamide)

Snippet

Status: Authorised. Therapeutic area: Parkinson Disease. MAH: Zambon SpA. Decision date: 09/02/2026